As behind the scenes negotiations to purchase Allergan, Inc. (NYSE:AGN) are ongoing – and ValueWalk sources who had been providing a steady stream of behind the scenes information take a more circumspect tone – comes a Bank of Montreal analysis that supports Allergan’s claims that they have won the important hearts and minds of doctors. Valeant and Allergan fighting to win support of ophthalmologists Doctors and more specifically ophthalmologists are a key influencer in the decision making process to purchase Allergan’s products. As reported in The Wall Street Journal, both Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) and Allergan, Inc. (NYSE:AGN)…
BMO Study Says Doctors Don't Like Valeant / Allergan Merger
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.